Incyte (INCY) Cash from Investing Activities Growth (1y) (2011 - 2026)
Incyte (INCY) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | -8,140.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,140.38% |
| Dec 31, 2025 | -74.33% |
| Sep 30, 2025 | -223.89% |
| Jun 30, 2025 | -108.83% |
| Mar 31, 2025 | 101.50% |
| Dec 31, 2024 | 86.11% |
| Sep 30, 2024 | 322.67% |
| Jun 30, 2024 | 2,978.18% |
| Mar 31, 2024 | -156.00% |
| Dec 31, 2023 | -638.81% |
| Sep 30, 2023 | 39.48% |
| Jun 30, 2023 | 40.47% |
| Mar 31, 2023 | -70.52% |
| Dec 31, 2022 | 68.34% |
| Sep 30, 2022 | 13.29% |
| Jun 30, 2022 | 74.61% |
| Mar 31, 2022 | 71.97% |
| Dec 31, 2021 | 35.71% |
| Sep 30, 2021 | -126.62% |
| Jun 30, 2021 | -13.61% |